Arbutus Biopharma (ABUS) Other Non-Current Liabilities (2011 - 2026)

Arbutus Biopharma (ABUS) has reported Other Non-Current Liabilities for 16 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 18.24% year-over-year to $8.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.6 million (down 18.24% YoY) and the FY2025 annual result came in at $8.4 million, down 17.9% from the prior year.
• Other Non-Current Liabilities climbed to $8.6 million in Q1 2026 per ABUS's latest filing, from $8.4 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ABUS reached as high as $15.4 million in Q1 2022 and fell as low as $7.6 million in Q4 2023.
• A 5-year average of $10.0 million and a median of $9.4 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities plunged 39.22% — and 2025, when it surged 35.27%.
• Year by year, Other Non-Current Liabilities stood at $10.4 million in 2022, then retreated by 26.68% to $7.6 million in 2023, then soared by 34.54% to $10.2 million in 2024, then fell by 17.9% to $8.4 million in 2025, then rose by 2.49% to $8.6 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $8.6 million, $8.4 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.